NasdaqGS:KMDA

Stock Analysis Report

Executive Summary

Kamada Ltd. develops, produces, and markets plasma-derived protein therapeutics for orphan indications.

Snowflake

Fundamentals

Very undervalued with outstanding track record.


Similar Companies

Share Price & News

How has Kamada's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-4.6%

NasdaqGS:KMDA

-0.2%

US Biotechs

-1.0%

US Market


1 Year Return

-2.6%

NasdaqGS:KMDA

-8.1%

US Biotechs

-0.4%

US Market

KMDA outperformed the Biotechs industry which returned -10% over the past year.

KMDA matched the United States of America Market (-1.7%) over the past year.


Share holder returns

KMDAIndustryMarket
7 Day-4.6%-0.2%-1.0%
30 Day-11.1%-0.2%-3.3%
90 Day-7.3%2.4%0.4%
1 Year-2.6%-2.6%-7.3%-8.1%1.8%-0.4%
3 Year24.9%24.9%9.7%5.9%39.4%30.4%
5 Year-19.4%-19.4%7.8%2.8%54.2%37.1%

Price Volatility Vs. Market

How volatile is Kamada's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Kamada undervalued based on future cash flows and its price relative to the stock market?

>50%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

Kamada's share price is below the future cash flow value, and at a moderate discount (> 20%).

Kamada's share price is below the future cash flow value, and at a substantial discount (> 40%).


Price Based on Earnings

Kamada is good value based on earnings compared to the US Biotechs industry average.

Kamada is good value based on earnings compared to the United States of America market.


Price Based on Expected Growth

Kamada is good value based on expected growth next year.


Price Based on Value of Assets

Kamada is good value based on assets compared to the US Biotechs industry average.


Next Steps

Future Growth

How is Kamada expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

9.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Kamada's revenue is expected to decrease over the next 1-3 years, this is not considered high growth.

Kamada's earnings are expected to grow by 9.8% yearly, however this is not considered high growth (20% yearly).

Kamada's revenues are expected to decrease over the next 1-3 years, this is below the United States of America market average.

Kamada's earnings growth is positive but not above the United States of America market average.

Kamada's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Kamada will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Kamada performed over the past 5 years?

70.0%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Kamada has delivered over 20% year on year earnings growth in the past 5 years.

Kamada's 1-year earnings growth exceeds its 5-year average (103.9% vs 70%)

Kamada's earnings growth has exceeded the US Biotechs industry average in the past year (103.9% vs 78.4%).


Return on Equity

Kamada has efficiently used shareholders’ funds last year (Return on Equity greater than 20%).


Return on Assets

Kamada used its assets more efficiently than the US Biotechs industry average last year based on Return on Assets.


Return on Capital Employed

Kamada has become profitable over the past 3 years. This is considered to be a significant improvement in its use of capital (Return on Capital Employed).


Next Steps

Financial Health

How is Kamada's financial position?


Financial Position Analysis

Kamada is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Kamada's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Kamada's level of debt (4.8%) compared to net worth is satisfactory (less than 40%).

The level of debt compared to net worth has been reduced over the past 5 years (20.9% vs 4.8% today).

Debt is well covered by operating cash flow (342.3%, greater than 20% of total debt).

Kamada earns more interest than it pays, coverage of interest payments is not a concern.


Balance Sheet

High level of physical assets or inventory.

Debt is covered by short term assets, assets are 21.4x debt.


Next Steps

Dividend

What is Kamada's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Kamada's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Kamada's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Kamada has not reported any payouts.

Unable to verify if Kamada's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Kamada has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Kamada's salary, the management and board of directors tenure and is there insider trading?

2.8yrs

Average management tenure


CEO

Amir London (50yo)

4.1yrs

Tenure

US$549,368

Compensation

Mr. Amir London has been the Chief Executive Officer at Kamada Ltd. since July 1, 2015. Mr. London served as an Senior Vice President of Business Development at Kamada Ltd. from December 9, 2013 to July 1, ...


CEO Compensation Analysis

Amir's remuneration is lower than average for companies of similar size in United States of America.

Amir's compensation has been consistent with company performance over the past year, both up more than 20%.


Management Age and Tenure

2.8yrs

Average Tenure

49yo

Average Age

The tenure for the Kamada management team is about average.


Board Age and Tenure

3.0yrs

Average Tenure

67yo

Average Age

The tenure for the Kamada board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Chaime Orlev (49yo)

    Chief Financial Officer

    • Tenure: 1.7yrs
    • Compensation: $305.70k
  • Amir London (50yo)

    Chief Executive Officer

    • Tenure: 4.1yrs
    • Compensation: $549.37k
  • David Tsur (68yo)

    Co-Founder & Active Deputy Chairman

    • Tenure: 29.6yrs
    • Compensation: $300.00k
  • Eran Nir (46yo)

    Vice President of Operations

    • Tenure: 2.8yrs
    • Compensation: $288.21k
  • Ariella Raban (43yo)

    Vice President of Human Resources

    • Tenure: 1.3yrs
  • Orna Naveh

    General Counsel & Corporate Secretary


Board Members

  • Jonathan Hahn (36yo)

    Director

    • Tenure: 9.4yrs
  • Avi Berger (67yo)

    Independent Director

    • Tenure: 3.0yrs
  • Efrat Makov (50yo)

    Director

    • Tenure: 0.7yrs
  • Milky Rubinstein (79yo)

    Independent director

    • Tenure: 1.7yrs
  • Michael Berelowitz (75yo)

    Independent Director

    • Tenure: 4.0yrs
  • Leon Recanati (71yo)

    Chairman

    • Tenure: 6.4yrs
  • Asaf Frumerman (34yo)

    Director

    • Tenure: 0.6yrs
  • Itzhak Krinsky (66yo)

    Independent director

    • Tenure: 1.7yrs
  • David Tsur (68yo)

    Co-Founder & Active Deputy Chairman

    • Tenure: 4.1yrs
    • Compensation: $300.00k

Company Information

Kamada Ltd.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Kamada Ltd.
  • Ticker: KMDA
  • Exchange: NasdaqGS
  • Founded: 1990
  • Industry: biotechnology
  • Sector: pharmaceuticals & biotech
  • Market Cap: ₪753.518m
  • Listing Market Cap: ₪212.630m
  • Shares outstanding: 40.30m
  • Website: Click here

Number of Employees


Location

  • Kamada Ltd.
  • 2 Holzman Street
  • Science Park
  • Rehovot
  • 7670402
  • Israel

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
KMDATASE (The Tel-Aviv Stock Exchange)YesOrdinary SharesILILSSep 2005
KMDANasdaqGS (Nasdaq Global Select)YesOrdinary SharesUSUSDSep 2005

Biography

Kamada Ltd. develops, produces, and markets plasma-derived protein therapeutics for orphan indications. It operates through two segments, Proprietary Products and Distribution. The company offers respirato ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/17 00:11
End of Day Share Price2019/08/16 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.